<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="203726">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437229</url>
  </required_header>
  <id_info>
    <org_study_id>NKV100787</org_study_id>
    <nct_id>NCT00437229</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety &amp; Interaction Between GW679769, Dexamethasone, &amp; Ondansetron When Taken by Healthy Adults</brief_title>
  <official_title>An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant [GW679769] and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron When Administered in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GW679769 may affect liver enzymes that metabolize dexamethasone and ondansetron. This study
      is designed to test the safety and the extent of the GW679769 affect on dexamethasone and
      ondansetron levels in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Period 1 &amp; 2: Plasma levels of casopitant, dexamethasone, &amp; ondansetron will be checked on Day 1, 2 and/or 3. Part B: Period 1, 2 &amp; 3: Plasma levels of casopitant, dexamethasone, &amp; ondansetron will be checked on Day 1, 2 and/or 3.</measure>
    <time_frame>checked on Day 1, 2 and/or 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety is evaluated by: Clinical Lab Tests done</measure>
    <time_frame>at Screening, Day -1 &amp; Followup.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitals Signs taken &amp; Adverse Events monitored</measure>
    <time_frame>at each visit starting at Day -1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 lead ECGs &amp; Serum Pepsinogen level tests</measure>
    <time_frame>at Screening &amp; Followup.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Nausea and Vomiting, Chemotherapy-Induced</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW679769 Oral Tablets</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone oral tablets &amp; intravenous</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron oral tablets &amp; intravenous</intervention_name>
    <other_name>GW679769 Oral Tablets</other_name>
    <other_name>dexamethasone oral tablets &amp; intravenous</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males or females

          -  Age: 18 to 55 years, inclusive

          -  A female subject who is non-childbearing potential or using acceptable contraceptive
             methods.

          -  Adequate organ systems function

          -  Able to swallow and retain oral medication

          -  Able to understand and comply with protocol requirements and instruction and is
             likely to complete the study.

        Exclusion Criteria:

          -  Cannot participation if subject has a clinically relevant abnormality, medical
             condition, or circumstance that makes them unsuitable for the study per the study
             doctor.

          -  History of drug or other allergy which, in the opinion of the Investigator,
             contraindicates participation.

          -  Use of an investigation drug within 28 days or 5 half-lives.

          -  Blood donation in excess of 500mL within 56 days prior to dosing or intends to donate
             within 30 days of the post-treatment follow-up visit.

          -  Presence of or suspected iron deficiency

          -  Positive stool for occult blood

          -  Female subject who is lactating

          -  Positive urine drug screen

          -  Positive for HIV antibody, hepatitis C antibody or hepatitis B surface antigen

          -  Use of tobacco-containing products within the past 12 months prior to screening

          -  History of drug or alcohol abuse or dependence within 6 months of screening

          -  History or presence of uncontrolled emesis

          -  Positive purified protein derivative (PPD) skin test for tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Johnson B, Adams L, Lu E, Zhang K, Lebowitz P, Lates C, Blum R. Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer. 2009 Sep;17(9):1177-85. doi: 10.1007/s00520-008-0571-5. Epub 2009 Feb 10.</citation>
    <PMID>19205755</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>May 31, 2012</lastchanged_date>
  <firstreceived_date>February 16, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW679769,</keyword>
  <keyword>Casopitant,</keyword>
  <keyword>Dexamethasone,</keyword>
  <keyword>Healthy Human Volunteer</keyword>
  <keyword>Ondansetron,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Casopitant</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
